{"id":426692,"date":"2026-10-11T07:04:35","date_gmt":"2026-10-11T07:04:35","guid":{"rendered":"https:\/\/malwaretips.com\/blogs\/?p=426692"},"modified":"2026-10-12T01:13:27","modified_gmt":"2026-10-12T01:13:27","slug":"theranos-scam-blood-testing-fraud-explained","status":"publish","type":"post","link":"https:\/\/malwaretips.com\/blogs\/theranos-scam-blood-testing-fraud-explained\/","title":{"rendered":"Theranos Scam Explained: How the Blood-Testing Promise Became a Fraud Case"},"content":{"rendered":"<p>A tiny blood sample, a long list of answers, and fewer uncomfortable trips to the lab. The Theranos promise sounded like medicine finally catching up with convenience.<\/p><div id=\"mwtad1439612582\" class=\"gas_fallback-ad_309684--placement_406659\" style=\"margin-top: 50px;margin-right: 10px;margin-bottom: 50px;margin-left: 10px;\"><script async src=\"\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-7750719144850257\" crossorigin=\"anonymous\"><\/script><ins class=\"adsbygoogle\" style=\"display:block;\" data-ad-client=\"ca-pub-7750719144850257\" \ndata-ad-slot=\"3957935887\" \ndata-ad-format=\"auto\" data-full-width-responsive=\"true\"><\/ins>\n<script> \n(adsbygoogle = window.adsbygoogle || []).push({}); \n<\/script>\n<\/div>\n<p>People wanted that promise to work. Understanding what happened means looking beyond the famous founder and following the claims patients and investors were asked to trust.<\/p>\n<figure><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-426693\" width=\"1672\" height=\"941\" src=\"https:\/\/malwaretips.com\/blogs\/wp-content\/uploads\/2026\/10\/theranos-scam-blood-testing-fraud-explained-image-1.png\" alt=\"Illustrative screen showing the small-sample blood-testing marketing promise, not an authentic Theranos page or medical result\" title=\"\" srcset=\"https:\/\/malwaretips.com\/blogs\/wp-content\/uploads\/2026\/10\/theranos-scam-blood-testing-fraud-explained-image-1.png 1672w, https:\/\/malwaretips.com\/blogs\/wp-content\/uploads\/2026\/10\/theranos-scam-blood-testing-fraud-explained-image-1-300x169.png 300w, https:\/\/malwaretips.com\/blogs\/wp-content\/uploads\/2026\/10\/theranos-scam-blood-testing-fraud-explained-image-1-1024x576.png 1024w, https:\/\/malwaretips.com\/blogs\/wp-content\/uploads\/2026\/10\/theranos-scam-blood-testing-fraud-explained-image-1-1536x864.png 1536w\" sizes=\"auto, (max-width: 1672px) 100vw, 1672px\" \/><\/figure>\n<div id=\"mwtad1974927825\" class=\"gas_fallback-ad_309746-ad_309685-placement_406660\" style=\"margin-top: 30px;margin-bottom: 30px;\"><script async src=\"\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-7750719144850257\" crossorigin=\"anonymous\"><\/script><ins class=\"adsbygoogle\" style=\"display:block;\" data-ad-client=\"ca-pub-7750719144850257\" \ndata-ad-slot=\"4456629336\" \ndata-ad-format=\"auto\" data-full-width-responsive=\"true\"><\/ins>\n<script> \n(adsbygoogle = window.adsbygoogle || []).push({}); \n<\/script>\n<\/div><h2>Overview<\/h2>\n<h3>A real company with a misleading central promise<\/h3>\n<p>The Theranos scam was a historical blood-testing and investor-fraud case involving a real company. It wasn&#8217;t simply a fake website that disappeared after collecting payments.<\/p><div id=\"mwtad2916533159\" class=\"gas_fallback-ad_381396-ad_309685-placement_406667\" style=\"margin-top: 50px;margin-bottom: 50px;\"><script async src=\"\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-7750719144850257\" crossorigin=\"anonymous\"><\/script><ins class=\"adsbygoogle\" style=\"display:block;\" data-ad-client=\"ca-pub-7750719144850257\" \ndata-ad-slot=\"1471373341\" \ndata-ad-format=\"auto\" data-full-width-responsive=\"true\"><\/ins>\n<script> \n(adsbygoogle = window.adsbygoogle || []).push({}); \n<\/script>\n<\/div>\n<p>Theranos presented its proprietary analyzer as a breakthrough capable of performing a broad range of tests from a small finger-stick sample.<\/p>\n<p>The problem was the gap between that presentation and the technology&#8217;s actual capabilities. Investors were sold claims that federal prosecutors later showed were materially false.<\/p>\n<p>Patient testing added another dimension. A convincing business pitch could affect a person&#8217;s understanding of their health, not just the value of an investment.<\/p><div id=\"mwtad2621449434\" class=\"gas_fallback-ad_309686-ad_309685-placement_406668\" style=\"margin-top: 50px;margin-right: 10px;margin-bottom: 50px;margin-left: 10px;\"><script async src=\"\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-7750719144850257\" crossorigin=\"anonymous\"><\/script><ins class=\"adsbygoogle\" style=\"display:block;\" data-ad-client=\"ca-pub-7750719144850257\" \ndata-ad-slot=\"6935453015\" \ndata-ad-format=\"auto\" data-full-width-responsive=\"true\"><\/ins>\n<script> \n(adsbygoogle = window.adsbygoogle || []).push({}); \n<\/script>\n<\/div>\n<p>This is an explanation of an established historical case. It is not a warning that an active Theranos laboratory is currently contacting readers.<\/p>\n<h3>The criminal outcomes were not identical<\/h3>\n<p>Elizabeth Holmes was convicted of an investor-fraud conspiracy and three investor-related wire-fraud counts. Her jury acquitted her of the patient-related counts it decided.<\/p>\n<p>Ramesh \u201cSunny\u201d Balwani faced a separate trial. His convictions covered both investor and patient fraud. Those different outcomes matter when describing either person&#8217;s conduct.<\/p><div id=\"mwtad3546784222\" class=\"gas_fallback-ad_381401-ad_309685-placement_406669\" style=\"margin-top: 50px;margin-right: 10px;margin-bottom: 50px;margin-left: 10px;\"><script async src=\"\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-7750719144850257\" crossorigin=\"anonymous\"><\/script><ins class=\"adsbygoogle\" style=\"display:block;\" data-ad-client=\"ca-pub-7750719144850257\" \ndata-ad-slot=\"5315249587\" \ndata-ad-format=\"auto\" data-full-width-responsive=\"true\"><\/ins>\n<script> \n(adsbygoogle = window.adsbygoogle || []).push({}); \n<\/script>\n<\/div>\n<p>The <a href=\"https:\/\/www.justice.gov\/usao-ndca\/us-v-elizabeth-holmes-et-al\" target=\"_blank\" rel=\"noopener\">Justice Department&#8217;s case overview<\/a> distinguishes the trials and sentences. A criminal verdict should not be expanded into convictions the jury never returned.<\/p>\n<h3>What readers should take from the case<\/h3>\n<p>The useful lesson is how an attractive promise can outgrow the evidence behind it. Convenience, prominent supporters, and business partnerships cannot independently validate a medical test.<\/p>\n<ul>\n<li><strong>For patients:<\/strong> a laboratory result needs a reliable method and appropriate clinical interpretation.<\/li>\n<li><strong>For investors:<\/strong> technical claims and business projections need separate checks.<\/li>\n<li><strong>For families:<\/strong> uncertainty about an old result belongs in a conversation with the treating clinician.<\/li>\n<li><strong>For everyone:<\/strong> a story about future possibilities is different from a demonstrated capability available today.<\/li>\n<\/ul>\n<div id=\"mwtad1671768529\" class=\"gas_fallback-ad_309747-ad_309685-placement_406661\" style=\"margin-top: 30px;margin-bottom: 30px;\"><script async src=\"\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-7750719144850257\" crossorigin=\"anonymous\"><\/script><ins class=\"adsbygoogle\" style=\"display:block;\" data-ad-client=\"ca-pub-7750719144850257\" \ndata-ad-slot=\"9589536513\" \ndata-ad-format=\"auto\" data-full-width-responsive=\"true\"><\/ins>\n<script> \n(adsbygoogle = window.adsbygoogle || []).push({}); \n<\/script>\n<\/div><h2>Why the Blood-Testing Story Was So Persuasive<\/h2>\n<h3>It addressed an ordinary frustration<\/h3>\n<div id=\"mwtad3070970049\" class=\"gas_fallback-ad_381404-ad_309685-placement_406670\" style=\"margin-top: 50px;margin-right: 10px;margin-bottom: 50px;margin-left: 10px;\"><script async src=\"\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-7750719144850257\" crossorigin=\"anonymous\"><\/script><ins class=\"adsbygoogle\" style=\"display:block;\" data-ad-client=\"ca-pub-7750719144850257\" \ndata-ad-slot=\"8735619847\" \ndata-ad-format=\"auto\" data-full-width-responsive=\"true\"><\/ins>\n<script> \n(adsbygoogle = window.adsbygoogle || []).push({}); \n<\/script>\n<\/div><p>Blood draws can be inconvenient, uncomfortable, expensive, or difficult to schedule. A smaller sample and faster answers offer benefits almost anyone can understand.<\/p>\n<p>That makes the opening claim unusually powerful. A patient doesn&#8217;t need specialist knowledge to picture a more pleasant appointment or an earlier answer to a worrying question.<\/p>\n<p>Wanting that improvement isn&#8217;t gullibility. The important question is whether the advertised process can deliver the promised result for the particular test being ordered.<\/p>\n<p>A simple experience at the counter can conceal a complicated process behind it. Taking a sample is only the beginning; measuring it reliably is the essential work.<\/p>\n<h3>A demonstration is not complete validation<\/h3>\n<p>Seeing a machine produce a number can feel like proof. It doesn&#8217;t explain whether that number remains accurate across different patients, conditions, and repeated measurements.<\/p>\n<p>A test can also be useful for one purpose without supporting every advertised use. Broad claims require evidence broad enough to match them.<\/p>\n<p>For a practical comparison, imagine a device that performs one measurement successfully. That achievement cannot automatically establish that it can replace a laboratory&#8217;s entire menu.<\/p>\n<p>Ask what was tested, against which reference method, and with what limitations. Clear answers are more useful than an impressive demonstration or a memorable slogan.<\/p>\n<h3>Recognition can stand in for verification<\/h3>\n<p>A recognizable retailer or a respected person can make a new service feel familiar. That familiarity may encourage customers to skip questions they would otherwise ask.<\/p>\n<p>Each relationship still has a specific meaning. A commercial arrangement isn&#8217;t necessarily an independent scientific endorsement of every claim appearing beside the partner&#8217;s name.<\/p>\n<p>For patients, the relevant issue is the actual testing service. For investors, it includes both the service and what a partnership contributes to the business.<\/p>\n<p>Those questions overlap, but they are not interchangeable. A store location can be real while a claim about the underlying technology remains misleading.<\/p>\n<div id=\"mwtad30677928\" class=\"gas_fallback-ad_309748-ad_309685-placement_406662\" style=\"margin-top: 30px;margin-bottom: 30px;\"><script async src=\"\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-7750719144850257\" crossorigin=\"anonymous\"><\/script><ins class=\"adsbygoogle\" style=\"display:block;\" data-ad-client=\"ca-pub-7750719144850257\" \ndata-ad-slot=\"3906789406\" \ndata-ad-format=\"auto\" data-full-width-responsive=\"true\"><\/ins>\n<script> \n(adsbygoogle = window.adsbygoogle || []).push({}); \n<\/script>\n<\/div><h2>How the Theranos Scam Worked<\/h2>\n<h3>Step 1: An ambitious goal was presented as an available capability<\/h3>\n<p>The public story centered on broad blood testing from a small sample. The analyzer was described as faster and more reliable than conventional approaches.<\/p>\n<p>According to the <a href=\"https:\/\/www.justice.gov\/usao-ndca\/pr\/theranos-founder-elizabeth-holmes-found-guilty-investor-fraud\" target=\"_blank\" rel=\"noopener\">Justice Department&#8217;s account of Holmes&#8217;s trial<\/a>, she knew the analyzer had accuracy problems and could perform only a limited number of tests.<\/p>\n<p>The distinction is crucial: an entrepreneur may pursue an ambitious goal, but describing an unfinished capability as already proven changes what customers and investors believe.<\/p>\n<p>Someone deciding to fund development needs to know what still requires development. Someone ordering a clinical test needs to know what will actually perform that test.<\/p>\n<p>Without that separation, people assess a finished breakthrough when the real situation is much narrower. The promise becomes the basis of their decision.<\/p>\n<h3>Step 2: Outside associations made the pitch look stronger<\/h3>\n<p>Trial evidence included misleading claims about pharmaceutical validation and military use. Familiar institutional names strengthened the impression that other experts had already checked the technology.<\/p>\n<p>A reader could reasonably assume that a prestigious association meant the hard technical questions had been answered. That assumption made further scrutiny feel less urgent.<\/p>\n<p>The general trap is borrowed authority. A logo, meeting, limited contract, or business relationship can be presented as something much broader than it actually is.<\/p>\n<p>To test that impression, identify the exact claim. Did another organization test the device, endorse its accuracy, buy a service, or merely discuss a possible arrangement?<\/p>\n<p>Ask what the partner actually checked. A familiar logo tells you very little if the advertised endorsement goes beyond that organization&#8217;s work.<\/p>\n<h3>Step 3: Conventional testing was obscured by the breakthrough story<\/h3>\n<p>Theranos used conventional machines purchased from third parties for much of its testing. That reality conflicted with the impression of a broadly capable proprietary analyzer.<\/p>\n<p>Using established equipment is not inherently fraudulent. The issue is representing what a company does in a way that misleads people about its special capabilities.<\/p>\n<p>Consider the difference between \u201cwe provide laboratory services\u201d and \u201cour unique analyzer performs this broad testing.\u201d They invite different conclusions about innovation, scalability, and value.<\/p>\n<p>Investors evaluating a proprietary platform may make different decisions from investors evaluating a business that relies heavily on ordinary equipment.<\/p>\n<p>Patients also need accurate information about the service they receive. They should not have to infer the testing method from a marketing narrative.<\/p>\n<h3>Step 4: Business expectations reinforced technical confidence<\/h3>\n<p>The pitch combined technology claims with an impressive business future. Revenue projections and expansion expectations could make the scientific story feel commercially confirmed.<\/p>\n<p>The <a href=\"https:\/\/www.sec.gov\/newsroom\/press-releases\/2018-41\" target=\"_blank\" rel=\"noopener\">SEC&#8217;s 2018 enforcement announcement<\/a> described false statements about technology, business relationships, and finances. Its civil allegations were separate from the later criminal verdicts.<\/p>\n<p>These claims can reinforce one another: promised growth makes the technology seem successful, while the technology story makes promised growth sound achievable.<\/p>\n<p>A careful evaluation breaks that circle. Ask for evidence of the current technical capability, then examine current commercial performance without treating either promise as proof.<\/p>\n<h3>Step 5: The gap reached decisions with real consequences<\/h3>\n<p>Investors committed money based on a misleading picture. Patients relied on testing that could shape conversations about diagnoses, follow-up care, and treatment.<\/p>\n<p>The <a href=\"https:\/\/www.justice.gov\/usao-ndca\/pr\/theranos-president-sentenced-more-12-years-fraud-jeopardized-patient-health-and-bilked\" target=\"_blank\" rel=\"noopener\">Balwani sentencing announcement<\/a> discusses inaccurate patient results described at trial, including results that prompted unnecessary medical concern or treatment adjustments.<\/p>\n<p>Those examples explain the stakes; they are not a way to diagnose a reader&#8217;s own history. Individual test reports require individual clinical assessment.<\/p>\n<p>The fraud case therefore has two connected but distinct consequences: financial decisions based on misrepresentation and health decisions affected by unreliable information.<\/p>\n<p>One cannot be repaired simply by addressing the other. A financial complaint doesn&#8217;t resolve a clinical question, and a corrected test doesn&#8217;t automatically recover an investment.<\/p>\n<div id=\"mwtad719239881\" class=\"gas_fallback-ad_318930-ad_309685-placement_406663\" style=\"margin-top: 30px;margin-bottom: 30px;\"><script async src=\"\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-7750719144850257\" crossorigin=\"anonymous\"><\/script><ins class=\"adsbygoogle\" style=\"display:block;\" data-ad-client=\"ca-pub-7750719144850257\" \ndata-ad-slot=\"3818335085\" \ndata-ad-format=\"auto\" data-full-width-responsive=\"true\"><\/ins>\n<script> \n(adsbygoogle = window.adsbygoogle || []).push({}); \n<\/script>\n<\/div><h2>The Company Behind the Theranos Promise<\/h2>\n<h3>Its existence was never the scientific verdict<\/h3>\n<p>Theranos was an actual blood-testing company, not an invented name on a disposable checkout page. Its real-world presence helped the promise travel.<\/p>\n<p>A company&#8217;s existence answers whether an organization is operating. It doesn&#8217;t answer whether a particular claim about accuracy, performance, or reliability is true.<\/p>\n<p>This distinction remains valuable when assessing unfamiliar laboratories or health startups. Verify both the organization and the precise service, rather than allowing one check to replace another.<\/p>\n<h3>The test method mattered more than the branding<\/h3>\n<p>Patients receive a result, but the method determines whether the result deserves confidence. The important information includes what was measured and how the result was produced.<\/p>\n<p>Marketing may emphasize the sample size because it is easy to picture. Sample preparation, measurement limits, and quality control are less visible but clinically important.<\/p>\n<p>A clinician can help explain whether a test is suitable for the question being asked. Branding alone cannot provide that interpretation.<\/p>\n<h3>Partnerships needed their own boundaries<\/h3>\n<p>Retail availability and well-known associations contributed to the company&#8217;s credibility. Their actual meaning needed to be assessed separately from what the promotional story suggested.<\/p>\n<p>A sensible question is specific: \u201cWhat did this organization verify?\u201d That is more useful than asking whether a logo looks official.<\/p>\n<p>The answer might concern distribution, a limited evaluation, or a commercial relationship. None should silently become a guarantee covering every medical or business claim.<\/p>\n<h3>Civil settlements and criminal judgments are different<\/h3>\n<p>Holmes and Theranos agreed to settle the SEC&#8217;s 2018 charges without admitting or denying its allegations. That settlement was not itself a criminal conviction.<\/p>\n<p>Later jury findings must be described on their own terms. Holmes&#8217;s investor convictions and Balwani&#8217;s broader convictions should not be blended into one identical verdict.<\/p>\n<p>Call the conduct what it was, but keep the verdicts straight. An investor-fraud conviction is not a conviction on every charge filed.<\/p>\n<h2>Questions Worth Asking About Any New Testing Promise<\/h2>\n<h3>What does the test actually measure?<\/h3>\n<p>Start with the medical question, not the marketing category. A test that measures one marker may not diagnose a condition by itself.<\/p>\n<p>Ask who interprets the result and whether another test may be needed. A useful service should explain its limitations instead of treating questions as disloyalty.<\/p>\n<p>The <a href=\"https:\/\/www.fda.gov\/medical-devices\/in-vitro-diagnostics\/direct-consumer-tests\" target=\"_blank\" rel=\"noopener\">FDA&#8217;s direct-to-consumer testing guidance<\/a> explains why results should be discussed with a healthcare provider. Different tests have different purposes and review requirements.<\/p>\n<h3>Can the claimed advantage be checked independently?<\/h3>\n<p>\u201cBetter\u201d needs a comparison. Better accuracy, less discomfort, faster turnaround, and lower cost are separate benefits that require separate explanations.<\/p>\n<p>A lower price can be attractive without establishing medical quality. A more comfortable collection method also doesn&#8217;t establish that every advertised test works with that sample.<\/p>\n<p>Investors can apply the same discipline to commercial claims. Ask what is operating today, what remains a goal, and which evidence supports each statement.<\/p>\n<p>The SEC&#8217;s <a href=\"https:\/\/www.investor.gov\/introduction-investing\/general-resources\/news-alerts\/alerts-bulletins\/investor-bulletins\/private\" target=\"_blank\" rel=\"noopener\">private-placement investor bulletin<\/a> notes that exempt offerings still face antifraud rules. Being a private startup does not excuse misleading information.<\/p>\n<h2>What to Do if You Have Fallen Victim to This Scam<\/h2>\n<p>Because this is a historical case, the right response depends on whether your concern involves an old test, an investment, or a new message exploiting the story.<\/p>\n<ol>\n<li>\n<p><strong>Find the actual records.<\/strong> Gather laboratory reports, invoices, clinician correspondence, investment documents, and payment records relevant to your own experience.<\/p>\n<p>Keep dates and the original wording. A recollection of a headline is less useful than the report or statement connected to your decision.<\/p>\n<\/li>\n<li>\n<p><strong>Discuss unresolved health concerns with your clinician.<\/strong> Bring the old report and explain what happened afterward, including any follow-up testing or treatment changes.<\/p>\n<p>Let the clinician decide whether anything needs reassessment. Don&#8217;t stop medication, repeat every old test, or assume lasting harm solely because Theranos appeared on a report.<\/p>\n<\/li>\n<li>\n<p><strong>Separate medical questions from financial ones.<\/strong> Record the testing fee or investment separately from treatment expenses and other consequences.<\/p>\n<p>This helps the appropriate professional understand your concern. It also prevents a general fraud summary from being mistaken for proof of your individual loss.<\/p>\n<\/li>\n<li>\n<p><strong>Use official case information.<\/strong> Start with the Justice Department and relevant court records, not a message claiming a settlement is waiting for immediate collection.<\/p>\n<p>Check dates carefully. The case overview includes a patient questionnaire with a 2022 deadline; this article does not reopen that process.<\/p>\n<\/li>\n<li>\n<p><strong>Get advice about your particular options.<\/strong> A qualified attorney or relevant official victim-contact channel can explain whether any process applies to your circumstances.<\/p>\n<p>Don&#8217;t assume a conviction automatically creates an available refund or that a historical reporting form remains open. Eligibility, deadlines, and available remedies need separate confirmation.<\/p>\n<\/li>\n<li>\n<p><strong>Reject unexpected recovery fees.<\/strong> Someone demanding a release charge or banking login for a supposed Theranos payout should not control your next step.<\/p>\n<p>The FTC describes this second loss in its <a href=\"https:\/\/consumer.ftc.gov\/articles\/refund-and-recovery-scams\" target=\"_blank\" rel=\"noopener\">refund and recovery scam guidance<\/a>. Verify any claimed administrator independently before supplying information.<\/p>\n<\/li>\n<li>\n<p><strong>Preserve suspicious follow-up messages.<\/strong> Save the sender, destination, requested payment, and any claim about representing a regulator or court.<\/p>\n<p>Report new impersonation through the appropriate official channel. Do not forward medical records to an unknown person offering to \u201ccheck your eligibility.\u201d<\/p>\n<\/li>\n<\/ol>\n<h2>Frequently Asked Questions<\/h2>\n<h3>Was Theranos simply a failed startup?<\/h3>\n<p>No. A startup can fail without fraud, but this case produced criminal investor-fraud convictions. The issue included intentional misrepresentation, not merely disappointing development.<\/p>\n<h3>Was Elizabeth Holmes convicted of patient fraud?<\/h3>\n<p>Her jury acquitted her of the patient-related counts it decided. Her convictions concerned investors. Balwani&#8217;s separate trial resulted in convictions involving both groups.<\/p>\n<h3>Did Theranos use only its own analyzer?<\/h3>\n<p>No. Trial evidence showed substantial use of conventional third-party machines. The misleading impression about proprietary capabilities was central to the investor story.<\/p>\n<h3>Does an old Theranos result mean I am ill?<\/h3>\n<p>No individual diagnosis follows from the company&#8217;s fraud case. Take a relevant report and any unresolved concern to a clinician who can assess your history.<\/p>\n<h3>Are all small-sample blood tests scams?<\/h3>\n<p>No. Evaluate the particular test, method, evidence, and intended use. Theranos&#8217;s conduct does not establish that every convenient testing method is unreliable.<\/p>\n<h3>Can someone guarantee recovery of a Theranos loss?<\/h3>\n<p>No legitimate guarantee follows from this article. Verify actual legal processes independently and avoid unsolicited demands for fees to release a supposed payout.<\/p>\n<h2>The Bottom Line<\/h2>\n<p>The Theranos scam turned an appealing testing promise into a misleading basis for serious decisions. Don&#8217;t treat its historical marketing as validated medical evidence.<\/p>\n<p>If an old result still concerns you, discuss the actual report with your clinician. For financial losses, verify applicable case information before trusting anyone promising recovery.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A tiny blood sample, a long list of answers, and fewer uncomfortable trips to the lab. The Theranos promise sounded like medicine finally catching up with convenience. People wanted that promise to work. Understanding what &#8230; <\/p>\n<p class=\"read-more-container\"><a title=\"Theranos Scam Explained: How the Blood-Testing Promise Became a Fraud Case\" class=\"read-more button\" href=\"https:\/\/malwaretips.com\/blogs\/theranos-scam-blood-testing-fraud-explained\/#more-426692\" aria-label=\"Read more about Theranos Scam Explained: How the Blood-Testing Promise Became a Fraud Case\">Read more<\/a><\/p>\n","protected":false},"author":51,"featured_media":426693,"comment_status":"open","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[49],"tags":[],"class_list":["post-426692","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-scam-reports","masonry-post","generate-columns","tablet-grid-50","mobile-grid-100","grid-parent","grid-50","resize-featured-image"],"_links":{"self":[{"href":"https:\/\/malwaretips.com\/blogs\/wp-json\/wp\/v2\/posts\/426692","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/malwaretips.com\/blogs\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/malwaretips.com\/blogs\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/malwaretips.com\/blogs\/wp-json\/wp\/v2\/users\/51"}],"replies":[{"embeddable":true,"href":"https:\/\/malwaretips.com\/blogs\/wp-json\/wp\/v2\/comments?post=426692"}],"version-history":[{"count":1,"href":"https:\/\/malwaretips.com\/blogs\/wp-json\/wp\/v2\/posts\/426692\/revisions"}],"predecessor-version":[{"id":426694,"href":"https:\/\/malwaretips.com\/blogs\/wp-json\/wp\/v2\/posts\/426692\/revisions\/426694"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/malwaretips.com\/blogs\/wp-json\/wp\/v2\/media\/426693"}],"wp:attachment":[{"href":"https:\/\/malwaretips.com\/blogs\/wp-json\/wp\/v2\/media?parent=426692"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/malwaretips.com\/blogs\/wp-json\/wp\/v2\/categories?post=426692"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/malwaretips.com\/blogs\/wp-json\/wp\/v2\/tags?post=426692"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}